- Home
- ATYR vs ASRT Comparison
ATYR vs ASRT Comparison
Compare ATYR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- ASRT
- Stock Information
- Founded
- ATYR 2005
- ASRT 1995
- Country
- ATYR United States
- ASRT United States
- Employees
- ATYR N/A
- ASRT N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ATYR Health Care
- ASRT Health Care
- Exchange
- ATYR Nasdaq
- ASRT Nasdaq
- Market Cap
- ATYR 228.1M
- ASRT 84.6M
- IPO Year
- ATYR 2015
- ASRT 1997
- Fundamental
- Price
- ATYR $3.30
- ASRT $0.89
- Analyst Decision
- ATYR Strong Buy
- ASRT Strong Buy
- Analyst Count
- ATYR 4
- ASRT 4
- Target Price
- ATYR $19.25
- ASRT $3.19
- AVG Volume (30 Days)
- ATYR 832.1K
- ASRT 933.9K
- Earning Date
- ATYR 11-07-2024
- ASRT 11-11-2024
- Dividend Yield
- ATYR N/A
- ASRT N/A
- EPS Growth
- ATYR N/A
- ASRT N/A
- EPS
- ATYR N/A
- ASRT N/A
- Revenue
- ATYR $235,000.00
- ASRT $125,763,000.00
- Revenue This Year
- ATYR N/A
- ASRT N/A
- Revenue Next Year
- ATYR $1,200.54
- ASRT $1.84
- P/E Ratio
- ATYR N/A
- ASRT N/A
- Revenue Growth
- ATYR N/A
- ASRT N/A
- 52 Week Low
- ATYR $1.34
- ASRT $0.73
- 52 Week High
- ATYR $3.80
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ATYR 52.43
- ASRT 42.24
- Support Level
- ATYR $3.05
- ASRT $0.90
- Resistance Level
- ATYR $3.26
- ASRT $1.04
- Average True Range (ATR)
- ATYR 0.22
- ASRT 0.07
- MACD
- ATYR -0.03
- ASRT -0.01
- Stochastic Oscillator
- ATYR 30.00
- ASRT 28.11
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.